Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03590743 · ClinicalTrials.gov registry record · Phase 4
Calf Deep Vein Thrombosis Treatment Trial
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03590743: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT03590743 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03590743, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective is to evaluate whether apixaban is more effective in treating patients with isolated calf vein thrombosis (DVT) than serial imaging of the DVT for preventing thrombus spread, pulmonary embolism (PE) and/or recurring DVTs.
Interventions
- OTHER Placebo
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2019-06-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03590743
The ClinicalTrials.gov registry entry for NCT03590743 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03590743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03590743 about?
NCT03590743 is a clinical study titled "Calf Deep Vein Thrombosis Treatment Trial". The primary objective is to evaluate whether apixaban is more effective in treating patients with isolated calf vein thrombosis (DVT) than serial imaging of the DVT for preventing thrombus spread, pulmonary embolism (PE) and/or recurring DVTs.
What is the current status of trial NCT03590743?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2019-02-19. Estimated completion is 2019-06-03.
What interventions are being tested in trial NCT03590743?
The interventions under investigation include: Placebo (OTHER), Apixaban (DRUG).
Who is sponsoring clinical trial NCT03590743?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.